| Consolidated net income | 3.35M |
| Depreciation and amortization | 2.55M |
| Stock-based compensation expense | 807K |
| Tax benefit from stock-based compensation expense | |
| Increase in receivable from Monsanto for guaranteed termination fee | |
| Deferred taxes | 1.73M |
| Change in investment in non-public company (fair market value) | |
| Accounts receivable, net | 2.26M |
| Accounts receivable, related party | |
| Income taxes receivable | |
| Inventories, net | -4.65M |
| Issuance of notes and advances receivable | |
| Collection of notes and advances receivable | |
| Prepaid expenses and other current assets | |
| Accounts payable | 709K |
| Related party accounts payable | |
| Accrued compensation | -1.42M |
| Other accrued liabilities | 1.61M |
| Deferred revenue | -126K |
| Net cash provided by operating activities | |
| Purchases of property and equipment | -2.13M |
| Purchase of marketable securities | |
| Proceeds from maturities and sales of marketable securities | |
| Net cash used in investing activities | |
| Repurchase of outstanding common stock | |
| Taxes paid by Company for stock swaps and RSUs | -272K |
| Tax benefit from stock-based compensation expense | |
| Principal payments on long-term debt | -1.91M |
| Decrease in other assets | -30K |
| Net cash provided by (used in) financing activities | |
| Net decrease in cash and cash equivalents | -1.27M |
| Cash and cash equivalents at beginning of period | 9.89M |
| Cash and cash equivalents at end of period | 8.63M |
| Income tax expense not payable | |
| Long-term receivable from Monsanto for guaranteed termination fee | |
| Unrealized loss from interest rate swap | |